Krystal Biotech Director Mason Christopher Receives Awards

What Happened Mason Christopher, a member of Krystal Biotech’s (KRYS) Board of Directors, received derivative compensation on September 14, 2026: 1,187 stock-option-type awards and 471 restricted stock units (RSUs). Both grants are reported at $0.00 (common for award grants) and are derivative awards rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-09-14; Form 4 filed 2026-09-16 (appears timely).
• Awards: 1,187 stock-option-type awards (derivative) and 471 RSUs, reported acquisition price $0.00.
• Vesting: Both the option awards and the RSUs vest in full on September 14, 2027, subject to continued Board service and earlier vesting in certain circumstances per the Company’s Non-Employee Director Compensation Policy (Footnotes F1–F3).
• RSU mechanics: Each RSU represents a contingent right to receive one share of common stock if vested (Footnote F2).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• No 10b5-1 plan, tax-withholding sale, or exercise-for-cash noted in this filing.

Context These are typical director compensation awards (not an open-market buy or sale). Awards vest contingent on continued service through the vest date, so they are retention-style grants rather than immediate transfers of shares. For retail investors, awards signal how the company compensates directors but do not directly reflect an insider buying or selling shares in the market.